Brachytherapy for targeting the immune system in cervical cancer patients

BackgroundNew combinations based on standard therapeutic modalities and immunotherapy require understanding the immunomodulatory properties of traditional treatments. The objective was to evaluate the impact of brachytherapy (BT) on the immune system of cervical cancer and to identify the best modal...

Descripción completa

Detalles Bibliográficos
Autores: Linares, Isabel, Berenguer Francés, Miguel Ángel, Cañas, Rut, Najjari, Dina, Gutiérrez, Cristina, Marín, Susanna, Comas, Silvia, Guedea, Ferran, Pujol, Monica
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2023
País:España
Institución:Universidad de Barcelona
Repositorio:Dipòsit Digital de la UB
OAI Identifier:oai:diposit.ub.edu:2445/202033
Acceso en línea:https://hdl.handle.net/2445/202033
Access Level:acceso abierto
Palabra clave:Càncer de coll uterí
Braquiteràpia
Cervix cancer
Radioisotope brachytherapy
id ES_b95ccbb5243f980bda406fa64f2de81e
oai_identifier_str oai:diposit.ub.edu:2445/202033
network_acronym_str ES
network_name_str España
repository_id_str
spelling Brachytherapy for targeting the immune system in cervical cancer patientsLinares, IsabelBerenguer Francés, Miguel ÁngelCañas, RutNajjari, DinaGutiérrez, CristinaMarín, SusannaComas, SilviaGuedea, FerranPujol, MonicaCàncer de coll uteríBraquiteràpiaCervix cancerRadioisotope brachytherapyBackgroundNew combinations based on standard therapeutic modalities and immunotherapy require understanding the immunomodulatory properties of traditional treatments. The objective was to evaluate the impact of brachytherapy (BT) on the immune system of cervical cancer and to identify the best modality, High-dose-rate brachytherapy (HDR-BT) vs. Pulsed-dose-rate (PDR-BT), to target it.MethodsNineteen patients enrolled in a prospective study received chemoradiation (CRT) and subsequently HDR-BT or PDR-BT. Peripheral blood samples were obtained for immunophenotyping analysis by flow-cytometry before CRT, BT, and two and four weeks after BT. The Friedman one-way ANOVA, Conover post hoc test, and the Wilcoxon signed-rank test were used to compare changes in cell populations at different periods, perform multiple pairwise comparisons and assess differences between treatment groups (PDR and HDR).ResultsNatural killer cells (NKs) were the best target for BT. Patients receiving HDR-BT achieved significantly higher values and longer time of the CD56dimCD16 + NK cells with greater cytotoxic capacity than the PDR-BT group, which presented their highest elevation of CD56-CD16 + NK cells. Furthermore, both BT modalities were associated with an increase in myeloid-derived suppressor cells (MDSCs), related to a worse clinical prognosis. However, there was a decrease in the percentage of CD4 + CD25 + Foxp3 + CD45RA + regulatory T cells (Tregs) in patients receiving HDR-BT, although there were no significant differences between BT.ConclusionsImmune biomarkers are important predictive determinants in cervical cancer. Higher cytotoxic NK cells and a trend toward lower values of Tregs might support the use of HDR-BT to the detriment of PDR-BT and help develop effective combinations with immunotherapy.Springer Science and Business Media LLC2023info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://hdl.handle.net/2445/202033Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))reponame:Dipòsit Digital de la UBinstname:Universidad de BarcelonaInglésReproducció del document publicat a: https://doi.org/10.1186/s12865-023-00559-yBMC Immunology, 2023, vol. 24, num. 1https://doi.org/10.1186/s12865-023-00559-ycc by (c) Linares, Isabel et al., 2023http://creativecommons.org/licenses/by/3.0/es/info:eu-repo/semantics/openAccessoai:diposit.ub.edu:2445/2020332026-05-27T06:46:51Z
dc.title.none.fl_str_mv Brachytherapy for targeting the immune system in cervical cancer patients
title Brachytherapy for targeting the immune system in cervical cancer patients
spellingShingle Brachytherapy for targeting the immune system in cervical cancer patients
Linares, Isabel
Càncer de coll uterí
Braquiteràpia
Cervix cancer
Radioisotope brachytherapy
title_short Brachytherapy for targeting the immune system in cervical cancer patients
title_full Brachytherapy for targeting the immune system in cervical cancer patients
title_fullStr Brachytherapy for targeting the immune system in cervical cancer patients
title_full_unstemmed Brachytherapy for targeting the immune system in cervical cancer patients
title_sort Brachytherapy for targeting the immune system in cervical cancer patients
dc.creator.none.fl_str_mv Linares, Isabel
Berenguer Francés, Miguel Ángel
Cañas, Rut
Najjari, Dina
Gutiérrez, Cristina
Marín, Susanna
Comas, Silvia
Guedea, Ferran
Pujol, Monica
author Linares, Isabel
author_facet Linares, Isabel
Berenguer Francés, Miguel Ángel
Cañas, Rut
Najjari, Dina
Gutiérrez, Cristina
Marín, Susanna
Comas, Silvia
Guedea, Ferran
Pujol, Monica
author_role author
author2 Berenguer Francés, Miguel Ángel
Cañas, Rut
Najjari, Dina
Gutiérrez, Cristina
Marín, Susanna
Comas, Silvia
Guedea, Ferran
Pujol, Monica
author2_role author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Càncer de coll uterí
Braquiteràpia
Cervix cancer
Radioisotope brachytherapy
topic Càncer de coll uterí
Braquiteràpia
Cervix cancer
Radioisotope brachytherapy
description BackgroundNew combinations based on standard therapeutic modalities and immunotherapy require understanding the immunomodulatory properties of traditional treatments. The objective was to evaluate the impact of brachytherapy (BT) on the immune system of cervical cancer and to identify the best modality, High-dose-rate brachytherapy (HDR-BT) vs. Pulsed-dose-rate (PDR-BT), to target it.MethodsNineteen patients enrolled in a prospective study received chemoradiation (CRT) and subsequently HDR-BT or PDR-BT. Peripheral blood samples were obtained for immunophenotyping analysis by flow-cytometry before CRT, BT, and two and four weeks after BT. The Friedman one-way ANOVA, Conover post hoc test, and the Wilcoxon signed-rank test were used to compare changes in cell populations at different periods, perform multiple pairwise comparisons and assess differences between treatment groups (PDR and HDR).ResultsNatural killer cells (NKs) were the best target for BT. Patients receiving HDR-BT achieved significantly higher values and longer time of the CD56dimCD16 + NK cells with greater cytotoxic capacity than the PDR-BT group, which presented their highest elevation of CD56-CD16 + NK cells. Furthermore, both BT modalities were associated with an increase in myeloid-derived suppressor cells (MDSCs), related to a worse clinical prognosis. However, there was a decrease in the percentage of CD4 + CD25 + Foxp3 + CD45RA + regulatory T cells (Tregs) in patients receiving HDR-BT, although there were no significant differences between BT.ConclusionsImmune biomarkers are important predictive determinants in cervical cancer. Higher cytotoxic NK cells and a trend toward lower values of Tregs might support the use of HDR-BT to the detriment of PDR-BT and help develop effective combinations with immunotherapy.
publishDate 2023
dc.date.none.fl_str_mv 2023
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/202033
url https://hdl.handle.net/2445/202033
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a: https://doi.org/10.1186/s12865-023-00559-y
BMC Immunology, 2023, vol. 24, num. 1
https://doi.org/10.1186/s12865-023-00559-y
dc.rights.none.fl_str_mv cc by (c) Linares, Isabel et al., 2023
http://creativecommons.org/licenses/by/3.0/es/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv cc by (c) Linares, Isabel et al., 2023
http://creativecommons.org/licenses/by/3.0/es/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Springer Science and Business Media LLC
publisher.none.fl_str_mv Springer Science and Business Media LLC
dc.source.none.fl_str_mv Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
reponame:Dipòsit Digital de la UB
instname:Universidad de Barcelona
instname_str Universidad de Barcelona
reponame_str Dipòsit Digital de la UB
collection Dipòsit Digital de la UB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869417765963563008
score 15,300724

Similares en LA Referencia